Custom service
Renaturation of Recombinant Proteins from Inclusion Bodies
Turning insoluble aggregates into folded protein — with a screen, not with hope.
Inclusion bodies are not dead material; they are concentrated, mostly pure, improperly folded protein waiting for the right conditions. The renaturation problem is that 'right conditions' is a high-dimensional space — denaturant concentration, redox potential, pH, salt, arginine, additives, temperature, protein concentration — and the difference between a productive refolding condition and an amorphous precipitate is often a single variable moved by a small amount.
The work starts with solubilisation: urea or guanidine at high concentration with a reducing agent, dissolving the inclusion body completely and confirming purity, since contaminants solubilise at different rates. Refolding is then screened, not attempted: a matrix of dilution and dialysis formats across denaturant gradients, redox pairs, arginine concentrations and additives, with each condition scored for soluble recovery and monomer content.
The screen's scoring matters as much as its breadth. Soluble protein that is still aggregated, or soluble but misfolded, fails the assay downstream; the screen therefore measures monomer content by SEC and, where possible, activity — because folded-but-inactive is the most common quiet failure. The winning condition is then scaled with the protein concentration controlled, since refolding yield drops sharply as concentration rises.
Renaturation is the route when a protein expresses only as inclusion bodies and a mammalian or periplasmic expression route is not viable — large proteins, toxic proteins, or constructs where expression yield makes inclusion bodies the cheapest source.
It is not the answer when the protein simply should be expressed solubly: if a construct change or a solubility tag solves the problem, that is cheaper than any refolding campaign.
The campaign report lists every screened condition with its soluble recovery, monomer content and activity score. The final batch carries SEC-HPLC, SDS-PAGE, endotoxin and functional data, and the refolding condition is documented for reproduction.
Service Highlights
- 96-condition screen. Denaturant, redox, pH, salt, arginine and additive combinations tested in parallel rather than tried one at a time.
- Two refolding formats. Rapid dilution and stepwise dialysis, since some proteins refold only under one.
- Monomer and activity scored. Conditions judged by SEC monomer content and functional recovery, not by soluble protein alone.
- Disulfide-aware redox. GSH/GSSG pairs and cysteine/cystine ratios optimised for the target's disulfide count.
- Concentration-managed scale-up. Refolding run at the protein concentration the screen validated, with pulsed or fed addition where higher loads are needed.
- Purification integrated. Refolded protein polished by ion exchange or SEC, with aggregate removed in the same campaign.
How the work runs
Inclusion body preparation
Bodies isolated, washed and solubilised; purity and completeness of solubilisation verified before refolding.
Refolding screen design
Matrix built around the target's disulfide count, size and class, with known precedents included.
Screen execution
Conditions run in plate format; soluble recovery measured at each.
Monomer and activity scoring
SEC and functional assay on the soluble fractions; misfolded-but-soluble conditions eliminated.
Scale-up
Refolding at the validated condition with protein concentration controlled; fed-batch addition where yield allows.
Polishing
Aggregate removal by SEC or ion exchange; final QC with monomer content and activity.
Specifications & timeline
- Protein classes
- Cytosolic, disulfide-bonded, multi-domain proteins
- Refolding formats
- Rapid dilution, stepwise dialysis, on-column refolding
- Screen size
- Up to 96 conditions per round; repeat rounds available
- Typical recovery
- 5–40% of solubilised protein as monomer
- Timeline
- 3–5 weeks per campaign
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.